Global Scleroderma Diagnostics and Therapeutics Industry

Global Scleroderma Diagnostics and Therapeutics Industry

  • April 2021 •
  • 180 pages •
  • Report ID: 6050305 •
  • Format: PDF
Abstract:
- Global Scleroderma Diagnostics and Therapeutics Market to Reach $4 Billion by 2027
- Amid the COVID-19 crisis, the global market for Scleroderma Diagnostics and Therapeutics estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2027, growing at aCAGR of 10.3% over the period 2020-2027. Localized, one of the segments analyzed in the report, is projected to record 9.5% CAGR and reach US$1.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Systemic segment is readjusted to a revised 11% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $598.9 Million, While China is Forecast to Grow at 9.6% CAGR
- The Scleroderma Diagnostics and Therapeutics market in the U.S. is estimated at US$598.9 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$692.8 Million by the year 2027 trailing a CAGR of 9.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.4% and 8.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

- Select Competitors (Total 42 Featured) -
  • Actelion Pharmaceuticals Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Corbus Pharmaceuticals Holdings, Inc.
  • Cumberland Pharmaceuticals, Inc.
  • Cytori Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Pfizer, Inc.
  • Sanofi SA